{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:42Z","timestamp":1793817582661,"version":"4.6.1"},"reference-count":56,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite idelalisib approval in relapsed follicular lymphoma (FL), a complete characterization of the immunomodulatory consequences of phosphatidylinositol 3-kinase \u03b4 (PI3K\u03b4) inhibition, biomarkers of response, and potential combinatorial therapies in FL remain to be established. Using ex vivo cocultures of FL patient biopsies and follicular dendritic cells (FDCs) to mimic the germinal center (n = 42), we uncovered that PI3K\u03b4 inhibition interferes with FDC-induced genes related to angiogenesis, extracellular matrix formation, and transendothelial migration in a subset of FL samples, defining an 18-gene signature fingerprint of idelalisib sensitivity. A common hallmark of idelalisib found in all FL cases was its interference with the CD40\/CD40L pathway and induced proliferation, together with the downregulation of proteins crucial for B\u2013T-cell synapses, leading to an inefficient cross talk between FL cells and the supportive T-follicular helper cells (TFH). Moreover, idelalisib downmodulates the chemokine CCL22, hampering the recruitment of TFH and immunosupressive T-regulatory cells to the FL niche, leading to a less supportive and tolerogenic immune microenvironment. Finally, using BH3 profiling, we uncovered that FL\u2013FDC and FL\u2013macrophage cocultures augment tumor addiction to BCL-XL and MCL-1 or BFL-1, respectively, limiting the cytotoxic activity of the BCL-2 inhibitor venetoclax. Idelalisib restored FL dependence on BCL-2 and venetoclax activity. In summary, idelalisib exhibits a patient-dependent activity toward angiogenesis and lymphoma dissemination. In all FL cases, idelalisib exerts a general reshaping of the FL immune microenvironment and restores dependence on BCL-2, predisposing FL to cell death, providing a mechanistic rationale for investigating the combination of PI3K\u03b4 inhibitors and venetoclax in clinical trials.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001584","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T15:39:29Z","timestamp":1599579569000},"page":"4217-4231","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["PI3K\u03b4 inhibition reshapes follicular lymphoma\u2013immune microenvironment cross talk and unleashes the activity of venetoclax"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-8451","authenticated-orcid":false,"given":"Neus","family":"Serrat","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Guerrero-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Matas-C\u00e9spedes","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anella","family":"Yahiaoui","sequence":"additional","affiliation":[{"name":"Department of Biomarker Sciences, Gilead Sciences, Inc., Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3193-9099","authenticated-orcid":false,"given":"Juan G.","family":"Valero","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-9440","authenticated-orcid":false,"given":"Ferran","family":"Nadeu","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-7413","authenticated-orcid":false,"given":"Guillem","family":"Clot","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Di Re","sequence":"additional","affiliation":[{"name":"Department of Haematology, Wellcome Medical Research Council Cambridge Stem Cell Institute, Cambridge, United Kingdom;"},{"name":"Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Corbera-Bellalta","sequence":"additional","affiliation":[{"name":"Vasculitis Research Unit, Department of Autoimmune Diseases, Clinical Institute of Medicine and Dermatology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS-CRB CELLEX), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-8386","authenticated-orcid":false,"given":"Laura","family":"Magnano","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"},{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-3415","authenticated-orcid":false,"given":"Alfredo","family":"Rivas-Delgado","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"},{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-6687","authenticated-orcid":false,"given":"Anna","family":"Enjuanes","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-2385","authenticated-orcid":false,"given":"Silvia","family":"Be\u00e0","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[{"name":"Vasculitis Research Unit, Department of Autoimmune Diseases, Clinical Institute of Medicine and Dermatology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS-CRB CELLEX), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-9793","authenticated-orcid":false,"given":"El\u00edas","family":"Campo","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"},{"name":"Hematopathology Unit, Department of Pathology, Hospital Cl\u00ednic\u2013IDIBAPS, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-4836","authenticated-orcid":false,"given":"Joan","family":"Montero","sequence":"additional","affiliation":[{"name":"Department of Nanobioengineering, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-2033","authenticated-orcid":false,"given":"Daniel J.","family":"Hodson","sequence":"additional","affiliation":[{"name":"Department of Haematology, Wellcome Medical Research Council Cambridge Stem Cell Institute, Cambridge, United Kingdom;"},{"name":"Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-8381","authenticated-orcid":false,"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"},{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7486-8484","authenticated-orcid":false,"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"},{"name":"Hematopathology Unit, Department of Pathology, Hospital Cl\u00ednic\u2013IDIBAPS, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Tannheimer","sequence":"additional","affiliation":[{"name":"Department of Biomarker Sciences, Gilead Sciences, Inc., Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3895-5024","authenticated-orcid":false,"given":"Patricia","family":"P\u00e9rez-Gal\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Oncolog\u00eda, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"issue":"4","key":"2020090811382795500_B1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2020090811382795500_B2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.beha.2017.10.006","article-title":"Pathogenesis of follicular lymphoma","volume":"31","author":"Lackraj","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"2020090811382795500_B3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcancer.2013.08.001","article-title":"The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity","volume":"24","author":"Am\u00e9-Thomas","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"16","key":"2020090811382795500_B4","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2015-04-640912","article-title":"DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma","volume":"126","author":"Amin","year":"2015","journal-title":"Blood"},{"issue":"16","key":"2020090811382795500_B5","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood-2015-04-640805","article-title":"Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells","volume":"126","author":"Linley","year":"2015","journal-title":"Blood"},{"issue":"43","key":"2020090811382795500_B6","doi-asserted-by":"crossref","first-page":"18587","DOI":"10.1073\/pnas.1009388107","article-title":"Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins","volume":"107","author":"Coelho","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2020090811382795500_B7","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2010.223","article-title":"Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis","volume":"24","author":"Pangault","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"2020090811382795500_B8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/leu.2011.301","article-title":"Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells","volume":"26","author":"Am\u00e9-Thomas","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"2020090811382795500_B9","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.4049\/jimmunol.1201363","article-title":"Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment","volume":"190","author":"Rawal","year":"2013","journal-title":"J Immunol"},{"issue":"5583","key":"2020090811382795500_B10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"issue":"11","key":"2020090811382795500_B11","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"2020090811382795500_B12","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2020090811382795500_B13","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020090811382795500_B14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2020090811382795500_B15","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020090811382795500_B16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1172\/JCI99386","article-title":"PI3K p110\u03b4 inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression","volume":"129","author":"Dong","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"2020090811382795500_B17","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1158\/2326-6066.CIR-14-0095","article-title":"Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway","volume":"2","author":"Abu-Eid","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"2020090811382795500_B18","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020090811382795500_B19","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.4049\/jimmunol.173.11.6676","article-title":"Follicular dendritic cells produce IL-15 that enhances germinal center B cell proliferation in membrane-bound form","volume":"173","author":"Park","year":"2004","journal-title":"J Immunol"},{"issue":"3","key":"2020090811382795500_B20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2004-01-0292","article-title":"Novel follicular dendritic cell molecule, 8D6, collaborates with CD44 in supporting lymphomagenesis by a Burkitt lymphoma cell line, L3055","volume":"104","author":"Li","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2020090811382795500_B21","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1084\/jem.191.6.1077","article-title":"Identification of a human follicular dendritic cell molecule that stimulates germinal center B cell growth","volume":"191","author":"Li","year":"2000","journal-title":"J Exp Med"},{"issue":"13","key":"2020090811382795500_B22","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1158\/1078-0432.CCR-14-0154","article-title":"Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib)","volume":"20","author":"Matas-C\u00e9spedes","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020090811382795500_B23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K-\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020090811382795500_B24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ng.3473","article-title":"Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma [published correction appears in Nat Genet. 2016;48:700]","volume":"48","author":"Okosun","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"2020090811382795500_B25","doi-asserted-by":"crossref","first-page":"e975624","DOI":"10.4161\/23723556.2014.975624","article-title":"PI3K at the crossroads of tumor angiogenesis signaling pathways","volume":"2","author":"Soler","year":"2015","journal-title":"Mol Cell Oncol"},{"issue":"3","key":"2020090811382795500_B26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/1074-7613(94)90095-7","article-title":"The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation","volume":"1","author":"Kawabe","year":"1994","journal-title":"Immunity"},{"issue":"5","key":"2020090811382795500_B27","doi-asserted-by":"crossref","first-page":"e97597","DOI":"10.1371\/journal.pone.0097597","article-title":"Mesenchymal stromal cells support the viability and differentiation of follicular lymphoma-infiltrating follicular helper T-cells","volume":"9","author":"Brady","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"2020090811382795500_B28","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-08-2360","article-title":"Regulatory T cells recruited through CCL22\/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome","volume":"69","author":"Gobert","year":"2009","journal-title":"Cancer Res"},{"issue":"9","key":"2020090811382795500_B29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"issue":"1","key":"2020090811382795500_B30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/intimm\/dxu079","article-title":"CCR4 and its ligands: from bench to bedside","volume":"27","author":"Yoshie","year":"2015","journal-title":"Int Immunol"},{"issue":"5","key":"2020090811382795500_B31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110\u03b4 isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J Immunol"},{"issue":"9","key":"2020090811382795500_B32","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"issue":"67","key":"2020090811382795500_B33","doi-asserted-by":"crossref","first-page":"112116","DOI":"10.18632\/oncotarget.22788","article-title":"T follicular helper cells: a potential therapeutic target in follicular lymphoma","volume":"8","author":"Ochando","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"2020090811382795500_B34","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/leu.2016.382","article-title":"Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2020090811382795500_B35","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2020090811382795500_B36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"},{"key":"2020090811382795500_B37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1101\/sqb.2016.81.030841","article-title":"To prime, or not to prime: that is the question","volume":"81","author":"Potter","year":"2016","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"5","key":"2020090811382795500_B38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"issue":"21","key":"2020090811382795500_B39","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2017-11-764365","article-title":"Critical influences on the pathogenesis of follicular lymphoma","volume":"131","author":"K\u00fcppers","year":"2018","journal-title":"Blood"},{"key":"2020090811382795500_B40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7554\/eLife.25541","article-title":"Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1","volume":"6","author":"Jenson","year":"2017","journal-title":"eLife"},{"issue":"2","key":"2020090811382795500_B41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","article-title":"Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery","volume":"91","author":"Datta","year":"1997","journal-title":"Cell"},{"issue":"5338","key":"2020090811382795500_B42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.278.5338.687","article-title":"Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt","volume":"278","author":"del Peso","year":"1997","journal-title":"Science"},{"issue":"7","key":"2020090811382795500_B43","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2020090811382795500_B44","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3324\/haematol.2009.021766","article-title":"Vascularization predicts overall survival and risk of transformation in follicular lymphoma","volume":"95","author":"Farinha","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2020090811382795500_B45","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood.V95.6.1900","article-title":"Cell adhesion receptors in lymphoma dissemination","volume":"95","author":"Drillenburg","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2020090811382795500_B46","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1200\/JCO.1999.17.6.1869","article-title":"Expression of beta-integrin adhesion molecules in non-Hodgkin\u2019s lymphoma: correlation with clinical and evolutive features","volume":"17","author":"Terol","year":"1999","journal-title":"J Clin Oncol"},{"issue":"14","key":"2020090811382795500_B47","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","article-title":"Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy","volume":"125","author":"de Rooij","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2020090811382795500_B48","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.4049\/jimmunol.1001730","article-title":"Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction","volume":"185","author":"Rolf","year":"2010","journal-title":"J Immunol"},{"issue":"7","key":"2020090811382795500_B49","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/10245332.2017.1300623","article-title":"The role of follicular T helper cells in patients with malignant lymphoid disease","volume":"22","author":"Zhou","year":"2017","journal-title":"Hematology"},{"issue":"1","key":"2020090811382795500_B50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4049\/jimmunol.0903505","article-title":"Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150)","volume":"185","author":"Yusuf","year":"2010","journal-title":"J Immunol"},{"key":"2020090811382795500_B51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fonc.2018.00458","article-title":"Hematologic tumor cell resistance to the BCL-2 inhibitor venetoclax: a product of its microenvironment?","volume":"8","author":"Leverson","year":"2018","journal-title":"Front Oncol"},{"issue":"14","key":"2020090811382795500_B52","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL [published correction appears in Blood Adv. 2017;1(19):1537]","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"issue":"7","key":"2020090811382795500_B53","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2020090811382795500_B54","first-page":"e302","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"2020090811382795500_B55","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Chiron","year":"2015","journal-title":"Oncotarget"},{"issue":"22","key":"2020090811382795500_B56","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/17\/4217\/1757441\/advancesadv2020001584.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/17\/4217\/1757441\/advancesadv2020001584.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T10:46:11Z","timestamp":1668681971000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/17\/4217\/463651\/PI3K%CE%B4-inhibition-reshapes-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":56,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001584","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]}}}